Cadonilimab Efficacy and Safety Meta-Analysis for Gastric Cancer

A 2025 meta-analysis by Likun Yang pooled results from four clinical studies involving 182 patients to evaluate the efficacy and safety of cadonilimab combined with chemotherapy for gastric or gastroesophageal junction adenocarcinoma. The analysis reports pooled objective response rate, disease control rate, progression-free survival, and adverse event incidence. The dataset is a structured summary of the meta-analysis results.

Use Cases

• Benchmarking treatment efficacy based on pooled objective response rate (ORR) and disease control rate (DCR) estimates
• Assessing treatment safety profiles based on the reported incidence of grade ≥3 treatment-related adverse events (TRAEs)
• Comparing outcomes across treatment settings using the subgroup analysis for neoadjuvant versus first-line therapy
• Informing clinical trial design based on the reported median progression-free survival (PFS) and pathological complete response (pCR) rates

Strengths

• Includes specific pooled efficacy metrics: ORR of 57%, DCR of 97%, and median PFS of 7.98 months
• Reports safety data with overall grade ≥3 TRAE incidence of 35% and subgroup comparisons
• Systematic review methodology with a PROSPERO registration identifier (CRD420251089855)

Limitations

• Row count is unknown, which may limit suitability assessment
• Column-level documentation is absent; field semantics must be inferred after download
• Based on a single-arm meta-analysis of four early-phase studies, limiting causal inference

Provenance

Source

Likun Yang

Collection Method

Systematic search and single-arm meta-analysis of clinical studies from PubMed, Embase, Cochrane Library, Web of Science, and ClinicalTrials.gov.

Time Range

Studies published up to July 20, 2025.

Freshness

Last updated 2026-03 17 13:07:24

Geography

null